Evidence map›Paper›PMID 40666898›Full record

ArticlebioRxiv : the preprint server for biology2025

Tre-DST: A new drug susceptibility test for

Lilith A Schwartz, Adriann L Brodeth, Cara T Susilo, Amelia A Rodolf, Tanya Ivanov, Esmeralda Mendoza Corrales, Shivani S Kumar, Mireille Kamariza

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Lilith A SchwartzUCLA Department of Chemistry and Biochemistry, Los Angeles, CA, USA.ORCID 0009-0002-3439-790X
Adriann L BrodethUCLA Department of Bioengineering, Los Angeles, CA, USA.ORCID 0009-0004-3084-0024
Cara T SusiloUCLA Department of Bioengineering, Los Angeles, CA, USA.ORCID 0009-0000-5059-4001
Amelia A RodolfUCLA Department of Bioengineering, Los Angeles, CA, USA.ORCID 0009-0003-3296-5392
Tanya IvanovUCLA Molecular Biology Institute, Los Angeles, CA, USA.ORCID 0009-0004-9692-7624
Esmeralda Mendoza CorralesUCLA Molecular Biology Institute, Los Angeles, CA, USA.ORCID 0000-0001-9182-0829
Shivani S KumarUCLA Department of Bioengineering, Los Angeles, CA, USA.ORCID 0009-0007-3561-7923
Mireille KamarizaUCLA Department of Bioengineering, Los Angeles, CA, USA.ORCID 0000-0003-1255-0803

Funding

Chemistry Biology Interface Training ProgramT32GM136614 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Patrick G. Harran · 2020 to 2026
$2.8M
A Rapid Phenotypic Drug Susceptibility Testing System for TuberculosisR01AI179891 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Mireille Kamariza · 2024 to 2026
$1.9M
Multiphoton Microscope for Deep Tissue ImagingS10OD025017 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BENTOLILA, LAURENT A. · 2018 to 2018
$599k
NIAID NIH HHS R01 AI179891NIGMS NIH HHS T32 GM136614NIH HHS S10 OD025017
6 · The paper itself

Abstract

Tuberculosis (TB) is the most lethal cause of death from a single infectious agent. In 2024, an estimated 10 million people developed TB, nearly half a million of which were infected with drug-resistant tuberculosis (DR-TB). Early detection of infection and drug resistance is critical to controlling DR-TB as this enables rapid engagement into effective care. Currently, bacterial culture and nucleic acid testing remain the primary methods for diagnosing infection, with smear microscopy being phased out. However, these methods present significant limitations for diagnosing drug resistance such as lengthy time-to-result for phenotypic tests, as well as the need for prior knowledge of resistance mutations and prohibitive cost for molecular tests. To address this, we developed a rapid phenotypic TB drug susceptibility test, termed Tre-DST, based on novel trehalose probes, which upon metabolic conversion emit enhanced fluorescence signal, giving them their unique ability to specifically detect live mycobacteria. We used the nonpathogenic

Identifiers

PMID40666898
PMCPMC12262397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.